Recombinant Mouse Activin RIA/ALK-2 Fc Chimera Protein, CF

Catalog #: 6506-RA Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
6506-RA-100

R&D Systems Recombinant Proteins and Enzymes

1 Image

All Activin RIA/ALK-2 Proteins and Enzymes

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse Activin RIA/ALK-2 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Mouse Activin RIA Fc Chimera is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Human BMP‑6 (Catalog # 507-BP) that produces 50% of the optimal binding response is found to be 6-60 ng/mL.

Source

Mouse myeloma cell line, NS0-derived mouse Activin RIA/ALK-2 protein

Mouse Activin RIA (Met1-Glu123) Accession # P37172	IEGRMDP	Mouse IgG_2A (Glu98-Lys330)
N-terminus		C-terminus

Accession #

P37172

N-terminal Sequence
Analysis

Asp23

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

38.4 kDa (monomer)

SDS-PAGE

45-50 kDa, reducing conditions

Product Datasheets

6506-RA

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

6506-RA

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 250 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: Activin RIA/ALK-2

Activin RIA, also known as ALK-2, TSK-7L, SKR1, TSR-I, and ACTR-I, is a glycosylated 65 kDa type I receptor in the TGF-beta serine/threonine kinase receptor family (1-3). Binding of TGF-beta superfamily ligands induces formation of a heterotetrameric complex that contains two chains each of a type I and a type II receptor in multiple combinations. The type II receptors phosphorylate the type I receptors which then phosphorylate and activate Smad signal transduction proteins (1, 2). Activin RIA functions in a wide variety of growth and differentiation processes including gastrulation, skeletal system development, and cardiac morphogenesis (1 4‑7). Mature mouse Activin RIA consists of a 103 aa extracellular domain (ECD), a 23 aa transmembrane segment, and a 363 aa cytoplasmic region that includes a Gly/Ser-rich GS box and the kinase domain (8). Within the ECD, mouse Activin RIA shares 99% and 93% aa sequence identity with human and rat Activin RIA, respectively. It shares 24%-26% aa sequence identity with other mouse type I receptors Activin RIB, BMPR-IA, BMPR-IB, and TGF-beta RI. BMP signaling through Activin RIA is enhanced by the direct interaction between Activin RIA and RGM-B/DRAGON, a BMP coreceptor that also associates with other type I and type II receptors (9). Activin RIA can additionally phosphorylate the co‑receptor Endoglin and blocks the inhibitory effect of Endoglin on prostate cancer cell motility (10).

References